Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the International Replication Repair Deficiency Consortium registry-based study
Findings from the GOG-0261 study
Efficacy and safety data in a larger number of patients and longer follow-up from KEYNOTE-158 study
Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol
RELATIVITY-047 validates LAG-3 as the third immune checkpoint inhibition pathway of clinical benefit
New indication concerns the treatment of patients with metastatic colorectal cancer for whom due to toxicity is not possible to continue treatment with another fluoropyrimidine
It is indicated for the treatment of adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping
Findings from the CheckMate 459 study
Findings from the ELARA study
New indication concerns the treatment of adult patients with ALK positive advanced NSCLC previously not treated with an ALK inhibitor
An antibody drug conjugate induces cytotoxicity in cancer cells by binding to the nectin-4
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
